ArticleScientific reports2026
Low-density lipoprotein cholesterol and risk of COPD: a Mendelian randomization study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Statins have shown effects on exacerbation rates and lung function in individuals with chronic obstructive pulmonary disease (COPD) in randomized controlled trials. This has led to speculation that elevated LDL cholesterol may increase the risk of adverse COPD outcomes. We tested the hypothesis that high LDL cholesterol is causally associated with increased risk of severe COPD exacerbation, COPD-specific mortality, and spirometric COPD through a one-sample Mendelian randomization study design using individual-level data in two cohorts. We examined 108,438 adults from the Copenhagen General Population Study (CGPS). A weighted allele score was calculated using nine biologically relevant genetic variants associated with LDL cholesterol levels, and causal risk estimates for the three outcomes were determined using instrumental variable analysis. Findings were validated using one-sample Mendelian randomization in 389,627 individuals from the UK Biobank (UKB). Causal odds ratios from the CGPS were not statistically significant for severe COPD exacerbation (odds ratio (OR) 1.12 (95% CI: 0.88–1.42), p = 0.34) or COPD-specific mortality (OR 1.08 (0.69–1.69), p = 0.74). Similar findings were seen in the UKB. Causal estimates showed a decreased risk of cross-sectional spirometric COPD with 1 mmol/L (39 mg/dL) higher LDL cholesterol in the CGPS (OR 0.78 (0.66–0.92), p < 0.001); however, causal estimates were not statistically significant in the UKB (OR 1.03 (0.95–1.11), p = 0.50). Sensitivity analyses using MR Egger, inverse-variance weighted, weighted median, and weighted mode methods did not indicate a true causal association for any outcome in either cohort. In conclusion, in the CGPS and UKB, high LDL cholesterol did not causally increase the risk of severe COPD exacerbation and COPD-specific mortality. Further, our findings do not provide consistent evidence to support a causal role of high LDL cholesterol in reducing the risk of developing COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.